Communicating Human Papillomavirus Vaccine With Japanese... | NCT06347627

NCT06347627

Status Module

Name	Class
London School of Hygiene and Tropical Medicine	OTHER
Nagasaki University	OTHER

Oversight Module

Description Module

Detailed Description

This study will implement an experiment as a sixteen-arm randomized controlled trial in an online survey environment. Before the experiment, participants, who are Japanese caregivers with daughters aged 12-18 who have not received an HPV vaccine, will first answer a pre-experiment survey. The survey will collect information on participants' socio-demographic data and key decision-making factors for HPV vaccine acceptance and confidence. Then, the study will randomly assign the participants to view one digital communication message using a 2 × 2 × 2 × 2 between-person factorial experiment on 'components of message.' The sixteen experimental messages will be developed based on real social media messages posted between November 2021 and April 2022, when the Japanese government prepared to reinstate an active recommendation of HPV vaccines for eligible girls after eight and a half years of suspension.

The sixteen messages will assess four factors: messenger, style, content, and misinformation. Each message will be similar except for one variable in consideration. The messenger component will be whether the message is from an individual or an organization. As individual messengers, the study will set a fictional male or female with common Japanese names who actively communicate about HPV vaccines. As organizational messengers, the study will use the existing accounts of the Ministry of Health, Labour and Welfare or the Japan Cancer Society or a fictional account of an anti-vaccine group. The style component will be whether the message conveys information through storytelling or scientific data. Messages will include personal stories for the storytelling style and statistics for the scientific data style. The content component will be whether the message conveys information about the effectiveness of the HPV vaccine in preventing diseases or the safety of the HPV vaccine. The contents will be built on both factual information and misconceptions about HPV vaccine safety and effectiveness that are often mentioned in the actual social media posts. The misinformation component will be whether the message conveys misinformation or factual information. The study will debrief all respondents exposed to misinformation after the survey.

Lastly, the study will collect data as a post-experiment survey to evaluate how an online message influenced caregivers' trust, confidence, and motivation to vaccinate.

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Group 1 (I x S x S x F)	Experimental	Participants in Group 1 will view a message in an X (former Twitter) format composed of "Individual x Safety x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.	Behavioral: Group 1 (I x S x S x F)
Group 2 (O x S x S x F)	Experimental	Participants in Group 2 will view a message in an X (former Twitter) format composed of "Organization x Safety x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.	Behavioral: Group 2 (O x S x S x F)
Group 3 (I x E x S x F)	Experimental	Participants in Group 3 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.	Behavioral: Group 3 (I x E x S x F)
Group 4 (O x E x S x F)	Experimental	Participants in Group 4 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Name	Type	Description	Arm Group Labels	Other Names
Group 1 (I x S x S x F)	Behavioral	Experimental message: Individual x Safety x Storytelling x Factual	Group 1 (I x S x S x F)

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Willingness to receive HPV vaccines for daughters	A degree of a change in willingness to receive HPV vaccines after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less willing to get the HPV vaccine for my daughter, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.	This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.

Secondary Outcomes

Measure	Description	Time Frame
Confidence in HPV vaccine safety	A degree of a change in confidence regarding HPV vaccine safety after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less confident that the HPV vaccine is safe, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.	This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.

Eligibility Module

Name	Affiliation	Role
Leesa Lin, PhD	London School of Hygiene and Tropical Medicine	Principal Investigator

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
40466485	Derived	Kobayashi K, Masuda K, Wu JT, Lin L. Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial. Vaccine. 2025 Aug 13;61:127327. doi: 10.1016/j.vaccine.2025.127327. Epub 2025 Jun 3.